Goldman Sachs
SUPN icon

Goldman Sachs’s Supernus Pharmaceuticals SUPN Stock Holding History

Goldman Sachs’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$44.3M Buy
856,487
+196,177
+30% +$9.99M 0.01% 1681
2025
Q4 		$32.8M Sell
660,310
-502,748
-43% -$24.4M ﹤0.01% 1874
2025
Q3 		$55.6M Buy
1,163,058
+266,671
+30% +$10.7M 0.01% 1340
2025
Q2 		$28.3M Buy
896,387
+72,232
+9% +$2.31M ﹤0.01% 1813
2025
Q1 		$27M Sell
824,155
-109,797
-12% -$3.89M ﹤0.01% 1743
2024
Q4 		$33.8M Buy
933,952
+34,315
+4% +$1.21M 0.01% 1623
2024
Q3 		$28.1M Buy
899,637
+309,304
+52% +$9.65M ﹤0.01% 1755
2024
Q2 		$15.8M Buy
590,333
+275,439
+87% +$7.98M ﹤0.01% 2071
2024
Q1 		$10.7M Buy
314,894
+75,763
+32% +$2.26M ﹤0.01% 2401
2023
Q4 		$6.92M Buy
239,131
+81,821
+52% +$2.17M ﹤0.01% 2864
2023
Q3 		$4.34M Sell
157,310
-33,863
-18% -$1.03M ﹤0.01% 3111
2023
Q2 		$5.75M Sell
191,173
-92,608
-33% -$3.24M ﹤0.01% 2984
2023
Q1 		$10.3M Sell
283,781
-35,078
-11% -$1.35M ﹤0.01% 2393
2022
Q4 		$11.4M Buy
318,859
+97,127
+44% +$3.38M ﹤0.01% 2462
2022
Q3 		$7.51M Sell
221,732
-85,751
-28% -$2.79M ﹤0.01% 2778
2022
Q2 		$8.89M Sell
307,483
-242,598
-44% -$6.95M ﹤0.01% 2623
2022
Q1 		$17.8M Buy
550,081
+285,737
+108% +$8.76M ﹤0.01% 2145
2021
Q4 		$7.71M Buy
264,344
+2,734
+1% +$82.9K ﹤0.01% 2997
2021
Q3 		$6.98M Buy
261,610
+10,254
+4% +$275K ﹤0.01% 3063
2021
Q2 		$7.74M Buy
251,356
+58,243
+30% +$1.79M ﹤0.01% 2941
2021
Q1 		$5.06M Sell
193,113
-153,127
-44% -$4.28M ﹤0.01% 3127
2020
Q4 		$8.71M Buy
346,240
+99,045
+40% +$2.13M ﹤0.01% 2578
2020
Q3 		$5.15M Buy
247,195
+8,230
+3% +$187K ﹤0.01% 2870
2020
Q2 		$5.68M Sell
238,965
-275,885
-54% -$6.1M ﹤0.01% 2702
2020
Q1 		$9.26M Sell
514,850
-184,163
-26% -$3.87M ﹤0.01% 2137
2019
Q4 		$16.6M Buy
699,013
+378,809
+118% +$9.2M ﹤0.01% 2022
2019
Q3 		$8.8M Buy
320,204
+150,673
+89% +$4.46M ﹤0.01% 2420
2019
Q2 		$5.61M Sell
169,531
-120,121
-41% -$4.12M ﹤0.01% 2765
2019
Q1 		$10.2M Buy
289,652
+65,125
+29% +$2.42M ﹤0.01% 2398
2018
Q4 		$7.46M Sell
224,527
-92,221
-29% -$3.97M ﹤0.01% 2556
2018
Q3 		$15.9M Sell
316,748
-129,954
-29% -$6.42M ﹤0.01% 2091
2018
Q2 		$26.7M Sell
446,702
-19,895
-4% -$1.03M 0.01% 1673
2018
Q1 		$21.4M Buy
466,597
+198,450
+74% +$8.28M 0.01% 1810
2017
Q4 		$10.7M Sell
268,147
-33,176
-11% -$1.31M ﹤0.01% 2413
2017
Q3 		$12.1M Buy
301,323
+96,484
+47% +$4.18M ﹤0.01% 2415
2017
Q2 		$8.83M Buy
204,839
+26,357
+15% +$938K ﹤0.01% 2602
2017
Q1 		$5.59M Sell
178,482
-40,180
-18% -$1.08M ﹤0.01% 2841
2016
Q4 		$5.52M Buy
218,662
+10,326
+5% +$231K ﹤0.01% 2963
2016
Q3 		$5.15M Buy
208,336
+169,922
+442% +$3.85M ﹤0.01% 3030
2016
Q2 		$782K Sell
38,414
-15,202
-28% -$270K ﹤0.01% 4419
2016
Q1 		$818K Buy
53,616
+19,840
+59% +$259K ﹤0.01% 4255
2015
Q4 		$454K Buy
+33,776
New +$522K ﹤0.01% 5004
2015
Q3 		– Sell
-104,799
Closed -$1.78M – 7485
2015
Q2 		$1.78M Buy
104,799
+87,752
+515% +$1.25M ﹤0.01% 3955
2015
Q1 		$206K Sell
17,047
-18,945
-53% -$179K ﹤0.01% 5994
2014
Q4 		$299K Buy
35,992
+20,341
+130% +$171K ﹤0.01% 5781
2014
Q3 		$136K Buy
15,651
+2,667
+21% +$24.1K ﹤0.01% 6424
2014
Q2 		$142K Sell
12,984
-16,296
-56% -$145K ﹤0.01% 6407
2014
Q1 		$262K Sell
29,280
-78,461
-73% -$723K ﹤0.01% 5836
2013
Q4 		$812K Buy
+107,741
New +$753K ﹤0.01% 4921

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs's SUPN Position: Q1 2026 in Review

Goldman Sachs increased its Supernus Pharmaceuticals (SUPN) stake by 30% in Q1 2026, buying an estimated $9.99M and bringing the position to 856,487 shares worth $44.3M. The position accounts for 0.01% of the portfolio, ranked #1681.

Goldman Sachs first reported a position in SUPN in Q4 2013 and has held it in 49 quarters since. The position peaked at $55.6M in Q3 2025. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

  • Goldman Sachs held 856,487 shares of Supernus Pharmaceuticals worth $44.3M as of Q1 2026.
  • Goldman Sachs bought 196,177 Supernus Pharmaceuticals shares in Q1 2026, an estimated $9.99M.
  • Supernus Pharmaceuticals made up 0.01% of Goldman Sachs's portfolio in Q1 2026, its #1681 holding.
  • Goldman Sachs first reported a position in Supernus Pharmaceuticals in Q4 2013 and has held it in 49 quarters since.
  • Goldman Sachs's Supernus Pharmaceuticals position peaked at $55.6M in Q3 2025.
  • 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.